Literature DB >> 8804913

In vitro hypoxia on rat pulmonary artery: effects on contractions to spasmogens and role of KATP channels.

J C Wanstall1, E O'Brien.   

Abstract

The effect of in vitro hypoxia for 1 h on concentration-response curves to vasoconstrictor spasmogens was examined in rat isolated pulmonary arteries. Hypoxia, like levcromakalim (KATP channel opener), did not affect contractions to endothelin-1 but attenuated contractions to U46619 ((1,5,5,)-hydroxy-11 alpha, 9 alpha-epoxymethano) prosta 5Z, 13E-dienoic acid; thromboxane-mimetic), angiotensin II, noradrenaline and 5-hydroxytryptamine. The attenuation was prevented by glybenclamide. In pre-contracted arteries, subsequent exposure to hypoxia caused a response consisting of four phases (transient relaxation due to endothelium-derived nitric oxide; transient contraction; slow relaxation; sustained contraction). Glybenclamide, if added before hypoxia, did not eliminate either of the relaxant phases but, if added during the sustained contractile phase, caused further contraction. We conclude that exposure of pulmonary arteries to prolonged hypoxia causes KATP channels to open, as in systemic arteries; this diminishes contractions to some, but not all, vasoconstrictor spasmogens. The data suggest that endothelin-1, unlike other vasoconstrictors, would remain a highly effective pulmonary vasoconstrictor under severe hypoxic conditions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8804913     DOI: 10.1016/0014-2999(96)00110-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Pulmonary vasodilation in the rat by insulin in vitro could indicate potential hazard for inhaled insulin.

Authors:  M Aye; W Sheedy; R Harrison; J S Thompson; A H Morice; E A Masson
Journal:  Diabetologia       Date:  2003-07-26       Impact factor: 10.122

Review 2.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.